A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
Mayo Clinic
Mayo Clinic
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
Stanford University
BerGenBio ASA
Stanford University
City of Hope Medical Center
Pfizer
Sumitomo Pharma America, Inc.
University of Nebraska
Bellicum Pharmaceuticals
Scripps Health
Roswell Park Cancer Institute
Northwestern University
Roswell Park Cancer Institute
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Celgene
Canadian Cancer Trials Group
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
University of California, San Francisco
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Wake Forest University Health Sciences
UNC Lineberger Comprehensive Cancer Center
Massachusetts General Hospital
OHSU Knight Cancer Institute
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Rutgers, The State University of New Jersey
University of Rochester
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Barbara Ann Karmanos Cancer Institute
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
Indiana University
Indiana University